Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1181-1200 of 1,743 trials

Melanoma Treatment: TILT-123 and Chemotherapy

We are studying a new oncolytic virus treatment combined with chemotherapy for patients with melanoma. This trial aims to see if this combination can improve treatment outcomes.

Melanoma>2 yearsSafety phase (I)DermatologyOncology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine

Hemorrhoidal Disease: RAFAELO® Procedure with Pain Management

We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.

Hemorrhoids>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Immunoglobulin A Nephropathy: Povetacicept Study

We are evaluating a new treatment for adults with Immunoglobulin A Nephropathy to see if it helps reduce protein in urine and preserve kidney function. The study also looks at its effects on slowing kidney failure and improving fatigue.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementNephrology

Non-Small Cell Lung Cancer: 68GaNOTA-Anti-MMR Imaging Study

We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngologyPulmonology

Multiple Myeloma: Elranatamab Combination Therapy

We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.

Multiple Myeloma>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

ANCA-Associated Vasculitis: Prednisone Treatment Study

We are investigating whether continuing low-dose prednisone helps maintain remission in patients with ANCA-associated vasculitis compared to stopping it after one month. This study will also look at potential side effects and relapse rates over time.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesRheumatology

HER2+ Metastatic Colorectal Cancer: Tucatinib Combination Study

We are investigating whether a new treatment combining tucatinib, trastuzumab, and mFOLFOX6 can improve outcomes for patients with HER2+ metastatic colorectal cancer compared to standard care.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: BGB-B3227 and Tislelizumab

We are testing a new treatment combining BGB-B3227 with Tislelizumab for patients with advanced or metastatic solid tumors. This study aims to understand how effective this combination may be in treating their condition.

Malignant Mast Cell Tumors>2 yearsSafety phase (I)Oncology

EBV Infection: Testing 2LEBV® and 2LXFS® for Fatigue

We are studying whether two new treatments can help reduce fatigue in patients with an EBV infection compared to a placebo. The trial also looks at other symptoms and safety.

Epstein-Barr Virus Infection>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesInfectious Diseases

Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

Malignant Solid Tumor>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Cholangiocarcinoma: Ivosidenib with Durvalumab and Gemcitabine/Cisplatin

We are studying a new treatment combination for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The goal is to evaluate its safety and early effectiveness as a first-line therapy.

Cholangiocarcinoma>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Headache Relief: Sphenopalatine Block for Subarachnoid Hemorrhage

We are studying whether a nerve block can help reduce headaches and the need for pain medication in patients with non-traumatic subarachnoid hemorrhage. This trial also looks at patient satisfaction and potential complications.

Subarachnoid Hemorrhage>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Pancreatic Cancer: Gemcitabine vs. Reduced-Dose Chemotherapy

We are studying whether standard-dose gemcitabine or a reduced-dose combination chemotherapy is more effective for fragile patients with non-resectable pancreatic cancer. This research aims to find the best treatment for those who cannot tolerate full-dose chemotherapy.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

FAPI PET Imaging for Pleural Mesothelioma

We are studying how effective FAPI PET scans are for diagnosing and staging pleural mesothelioma. This research may help improve treatment decisions and monitoring for patients with this condition.

Pleural Mesothelioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngology

Cancer Treatment: ABP 234 vs. Keytruda

We are comparing a new treatment called ABP 234 with Keytruda for patients with cancer. This study aims to see which option may be more effective in managing the disease.

Advanced Non-Squamous Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Inhaled Levosimendan: Understanding How It Works

We are exploring how the body processes inhaled levosimendan in this early study. This research may help improve treatments for heart conditions.

Heart Failure>2 yearsSafety phase (I)CardiologyInternal Medicine